Study guide

12.4 Oncology Support & Oral Anticancer Medicines

APC Intern Written Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals

2 Legal Framework: PBS & Medicine Schedules

2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)

3 Legal Framework: Privacy, National Law & Pharmacy Board

3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards

4 Patient-Centred Medication Management

4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management

5 Primary Care & Judicious Use of Medicines

5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices

6 Dispensing & Clinical Appropriateness

6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes

7 Counselling & Acute Care

7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response

8 Therapeutics: Cardiovascular & Endocrine

8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders

9 Therapeutics: Infection, Respiratory & Gastrointestinal

9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health

10 Therapeutics: Neurology, Psychiatry & Pain

10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics

11 Therapeutics: Special Populations & Systems

11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment

12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology

12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management

13 Monitoring: Clinical Review

13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications

14 Monitoring: Safety & Adverse Drug Reactions

14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring

15 Compounding Medicines

15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations

16 Pharmaceutical Calculations

16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations

17 Promote Health & Well-Being

17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency

12.4 Oncology Support & Oral Anticancer Medicines

Key Takeaways Explain This Topic AI

A fever of 38 degrees Celsius or above in a patient receiving chemotherapy is a medical emergency requiring immediate hospital assessment, not over-the-counter antipyretics.

Cytotoxic tablets and capsules must not be crushed, split or opened; contact the prescriber for an alternative if the patient cannot swallow.

Capecitabine markedly potentiates warfarin, and hand-foot syndrome or diarrhoea should prompt the patient to stop and contact the treating team.

Strong CYP2D6 inhibitors such as paroxetine and fluoxetine reduce tamoxifen activation to endoxifen, so antidepressant selection matters in breast cancer.

Oral anticancer regimens are commonly cycled with rest periods, so the cycle and next start date must be confirmed at every supply rather than assumed to be continuous.

Last updated: August 2026

12.4 Oncology Support & Oral Anticancer Medicines

Quick Answer: APC names oncology as an exam content area. Community pharmacists now dispense oral anticancer medicines routinely, so the examinable skills are safe handling, recognising febrile neutropenia as an emergency, screening over-the-counter requests against thrombocytopenia and interactions, and supporting adherence to complex cycled regimens.

Oncology reaches community pharmacy through three doors: oral anticancer medicines dispensed on ordinary prescriptions, supportive care for people between hospital cycles, and over-the-counter requests from patients whose blood counts change the safety of everyday products. All three sit inside Standards 3.2 and 3.3.

Safe handling of cytotoxic and hazardous medicines

Oral does not mean harmless to handle.

Wear gloves when counting or handling; prefer supplying in the original manufacturer's pack rather than repacking

Do not crush, split or open cytotoxic tablets or capsules; if the person cannot swallow, contact the prescriber for an alternative rather than improvising

Avoid including cytotoxics in dose administration aids unless a specific risk assessment supports it

Staff who are pregnant, breastfeeding or trying to conceive should follow the pharmacy's policy on handling hazardous medicines

Know your spill procedure and where the spill kit is

Counsel patients and carers on handling: gloves for carers, careful handling of vomit and body waste for a defined period after dosing, and returning unused medicines to the pharmacy rather than the bin

Oral anticancer medicines — high-yield counselling

Medicine Counselling and safety essentials

Capecitabine Take within about 30 minutes after food; hand-foot syndrome (painful red palms and soles) and diarrhoea are dose-limiting — tell the patient to stop and contact the treating team rather than push on; markedly potentiates warfarin , causing dangerous INR rises; DPD deficiency increases toxicity risk

Methotrexate (non-oncology) Weekly, not daily. A daily direction without an explicit verified specialist protocol must be resolved with the prescriber before supply

Tamoxifen Adherence over years is the main determinant of benefit; hot flushes are common; venous thromboembolism and endometrial changes need awareness — report calf pain, breathlessness or abnormal vaginal bleeding; strong CYP2D6 inhibitors such as paroxetine and fluoxetine reduce activation to endoxifen , so an antidepressant choice matters here

Aromatase inhibitors (anastrozole, letrozole, exemestane) Arthralgia is the leading reason for discontinuation — normalise it and offer strategies rather than let the patient quit silently; bone density loss requires monitoring, calcium and vitamin D review

Targeted oral agents (kinase inhibitors and similar) Many have significant food and interaction restrictions, including grapefruit and acid-suppressing medicines; always check the specific agent rather than generalising

Cycled regimens are an adherence hazard. Many oral regimens run, for example, two weeks on and one week off. A patient who "just keeps taking them" can be seriously over-treated. Confirm the cycle, the rest period and the next start date at every supply, and never assume a repeat means continuous therapy.

Febrile neutropenia — the emergency you must not miss

A person receiving chemotherapy who develops a fever of 38 °C or above , or who feels acutely unwell with rigors, requires immediate hospital assessment . Do not sell paracetamol and send them home; paracetamol can mask the fever that is the only visible sign.

Other urgent escalations: uncontrolled vomiting or diarrhoea with dehydration risk, mouth ulceration preventing eating or drinking, breathlessness, unexplained bruising or bleeding, and new severe pain.

Over-the-counter screening in a patient on chemotherapy

  • Request Concern
  • Aspirin or an NSAID Bleeding risk with thrombocytopenia ; renal risk with nephrotoxic regimens
  • Paracetamol for fever May mask febrile neutropenia — assess before supplying

Herbal products, especially St John's wort Potent enzyme induction can reduce anticancer drug concentrations; high-dose antioxidants may interact with treatment intent

Live vaccines Generally avoided during significant immunosuppression; inactivated vaccines are encouraged and timed with the treating team

Constipation remedies Frequently needed — 5-HT3 antagonists such as ondansetron and opioids both constipate

Ask, do not assume. Many patients do not consider complementary products to be "medicines" and will not mention them unless invited.

Supportive care essentials

Nausea and vomiting — prevention beats rescue. Regimens combine a 5-HT3 antagonist, dexamethasone and, for highly emetogenic protocols, an NK1 antagonist. Counsel on taking antiemetics as scheduled, not only when nauseated, and warn about ondansetron-induced constipation.

Mucositis — bland mouth care, saline or bicarbonate rinses, avoiding alcohol-containing mouthwashes, and escalation if the person cannot eat or drink.

Cancer pain — opioids are appropriate and should be titrated; always co-prescribe or recommend a laxative with a regular opioid, and counsel on breakthrough dosing versus background dosing.

Skin and nail care — sun protection is important with photosensitising agents; hand-foot syndrome prevention includes emollients and avoiding friction and heat.

Fertility, contraception and pregnancy — many agents are teratogenic; contraception advice extends beyond the treatment period and applies to both men and women.

Communication and cultural safety

Oncology conversations carry fear. Use plain language, check understanding, and be careful with prognosis language that is not yours to give. Offer a private consultation space, involve carers with the patient's consent, and use an interpreter where language is a barrier rather than relying on a family member. If a patient raises unproven "cures" they have read about, respond with honest, evidence-based information and encourage them to discuss it with the oncology team — do not ridicule, and do not endorse.

Exam mindset

Oncology items rarely ask you to choose a chemotherapy regimen. They ask whether you will recognise febrile neutropenia, whether you will check the cycle before supplying, whether you will spot capecitabine plus warfarin, and whether you will refuse to crush a cytotoxic tablet. Those are pharmacist decisions and they are exactly what Standards 3.2 and 3.3 assess.

PBS access and supply logistics

Many oral anticancer medicines are Authority required on the PBS, and the authority conditions are specific — a particular line of therapy, a documented disease stage, or evidence of prior treatment. Practical consequences at the counter:

Check that the authority approval number or streamlined code is present and matches the item and quantity before you supply

Confirm the quantity and repeats fit the prescribed cycle rather than a generic monthly assumption

Where an item is not PBS-subsidised for that indication, the private cost can be substantial — tell the patient before you order rather than after

Some medicines are supplied through hospital or specialist pharmacy arrangements; know when to redirect rather than promise a supply you cannot deliver

Dose administration aids are the other recurring logistics decision. Cytotoxic and hazardous medicines are generally excluded from packing because of contamination risk and because cycled dosing does not fit a weekly blister. If the patient needs adherence support, use a written cycle calendar, reminders and carer involvement instead.